These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 7303258)

  • 21. Safety of selective cyclooxygenase-2 inhibitors in inflammatory bowel disease.
    Mahadevan U; Loftus EV; Tremaine WJ; Sandborn WJ
    Am J Gastroenterol; 2002 Apr; 97(4):910-4. PubMed ID: 12008668
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunohistochemical localization of vascular endothelial growth factor in colonic mucosa of patients with inflammatory bowel disease.
    Griga T; May B; Pfisterer O; Müller KM; Brasch F
    Hepatogastroenterology; 2002; 49(43):116-23. PubMed ID: 11941933
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Response to Dai et al.
    Racine A; Boutron-Ruault MC; Carbonnel F
    Am J Gastroenterol; 2014 Sep; 109(9):1494-5. PubMed ID: 25196875
    [No Abstract]   [Full Text] [Related]  

  • 24. Epidemiology supports oral contraceptives as a risk factor in Crohn's disease.
    Alic M
    Gut; 2000 Jan; 46(1):140. PubMed ID: 10681185
    [No Abstract]   [Full Text] [Related]  

  • 25. [Familial prevalence in chronic intestinal inflammatory disease. Differences among groups of patients with and without a familial history].
    Nos P; Argüello L; Hoyos M; Ramírez JJ; Hinojosa J; Molés JR; García A; Berenguer M; Berenguer J
    Rev Esp Enferm Dig; 1996 Jul; 88(7):470-4. PubMed ID: 8924324
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased production of vascular endothelial growth factor by intestinal mucosa of patients with inflammatory bowel disease.
    Griga T; Voigt E; Gretzer B; Brasch F; May B
    Hepatogastroenterology; 1999; 46(26):920-3. PubMed ID: 10370639
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk of cervical abnormalities in women with inflammatory bowel disease: a population-based nested case-control study.
    Singh H; Demers AA; Nugent Z; Mahmud SM; Kliewer EV; Bernstein CN
    Gastroenterology; 2009 Feb; 136(2):451-8. PubMed ID: 18996382
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Editorial: bugs and drugs: insights into the pathogenesis of inflammatory bowel disease.
    Nguyen GC
    Am J Gastroenterol; 2011 Dec; 106(12):2143-5. PubMed ID: 22138941
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Study the effect and mechanism of thalidomide in model of inflammatory bowed disease].
    Wang X; Ouyang Q
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2005 Jul; 36(4):548-51. PubMed ID: 16078585
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The association of MYO9B gene in Italian patients with inflammatory bowel diseases.
    Latiano A; Palmieri O; Valvano MR; D'Incà R; Caprilli R; Cucchiara S; Sturniolo GC; Bossa F; Andriulli A; Annese V
    Aliment Pharmacol Ther; 2008 Feb; 27(3):241-8. PubMed ID: 17944996
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diagnostic yield of capsule endoscopy in ulcerative colitis and inflammatory bowel disease of unclassified type (IBDU).
    Mehdizadeh S; Chen G; Enayati PJ; Cheng DW; Han NJ; Shaye OA; Ippoliti A; Vasiliauskas EA; Lo SK; Papadakis KA
    Endoscopy; 2008 Jan; 40(1):30-5. PubMed ID: 18058654
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Current therapeutic possibilities in chronic inflammatory intestinal diseases].
    Schölmerich J
    Praxis (Bern 1994); 1995 Jan; 84(2):29-33. PubMed ID: 7839043
    [TBL] [Abstract][Full Text] [Related]  

  • 33. C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study.
    Henriksen M; Jahnsen J; Lygren I; Stray N; Sauar J; Vatn MH; Moum B;
    Gut; 2008 Nov; 57(11):1518-23. PubMed ID: 18566104
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Immunohistochemical study of HLA-DR expression in superficial epithelium and in lamina propria of colonic mucosa in children with Crohn's disease and nonspecific ulcerative colitis].
    Rodrigues M; Zerbini MC; Barbieri D
    Arq Gastroenterol; 1998; 35(2):143-51. PubMed ID: 9814381
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Indications for different collagen metabolism in Crohn disease and ulcerative colitis].
    Matthes H; Stallmach A; Matthes B; Herbst H; Schuppan D; Riecken EO
    Med Klin (Munich); 1993 Apr; 88(4):185-92. PubMed ID: 8492773
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Increased expression of VEGF and CD146 in patients with inflammatory bowel disease.
    Tsiolakidou G; Koutroubakis IE; Tzardi M; Kouroumalis EA
    Dig Liver Dis; 2008 Aug; 40(8):673-9. PubMed ID: 18374637
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Discussion of the article by Dr. J. Kocián: Crohn's disease and ulcerative colitis. Questions of risk factors, etiology and therapy of nonspecific intestinal inflammatory diseases].
    Kubát R
    Vnitr Lek; 1998 May; 44(5):297. PubMed ID: 9820077
    [No Abstract]   [Full Text] [Related]  

  • 38. [The role of infective intestinal complications on the course of Crohn's disease and ulcerative rectocolitis].
    Romagnoli AM; Corradini P; Matergi M; Schiaroli G; Moschini G; Incandela L; Galassi L
    Clin Ter; 1993 Jan; 142(1):53-9. PubMed ID: 8472512
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Unfractioned heparin in the therapy of patients with highly active inflammatory bowel disease.
    Folwaczny C; Wiebecke B; Loeschke K
    Am J Gastroenterol; 1999 Jun; 94(6):1551-5. PubMed ID: 10364024
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of a prodromal period in Crohn's disease but not ulcerative colitis.
    Pimentel M; Chang M; Chow EJ; Tabibzadeh S; Kirit-Kiriak V; Targan SR; Lin HC
    Am J Gastroenterol; 2000 Dec; 95(12):3458-62. PubMed ID: 11151877
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.